UK markets close in 8 hours 26 minutes
  • FTSE 100

    +25.80 (+0.36%)
  • FTSE 250

    0.00 (0.00%)
  • AIM

    0.00 (0.00%)

    +0.0027 (+0.24%)

    +0.0028 (+0.20%)

    -4.04 (-0.01%)
  • CMC Crypto 200

    -5.17 (-0.51%)
  • S&P 500

    -8.56 (-0.20%)
  • DOW

    -94.42 (-0.27%)

    +0.39 (+0.54%)

    +5.40 (+0.29%)
  • NIKKEI 225

    -150.29 (-0.51%)

    -157.30 (-0.55%)
  • DAX

    +55.88 (+0.36%)
  • CAC 40

    +23.17 (+0.35%)

Insights on the Adenosine Triphosphate Swab Test Global Market to 2027 - by Type, Application and Geography

·7-min read

Dublin, June 02, 2021 (GLOBE NEWSWIRE) -- The "Adenosine Triphosphate Swab Test Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type and Application" report has been added to's offering.

The adenosine triphosphate (ATP) swab test market was valued at US$ 198.21 million in 2019 and is projected to reach US$ 369.71 million by 2027; it is expected to grow at a CAGR of 8.10% from 2019 to 2027. The growth of the market is mainly attributed to the rising prevalence of healthcare associated infections (HAIs) and increasing emphasis on food safety. However, limitations of ATP swab tests limit the market growth.

HAIs, also known as nosocomial infections, are acquired while receiving treatment or therapies in healthcare facilities. These infections are related to surgical procedures and medical instruments used during procedures. HAIs are responsible for morbidity and mortality of significant number of patients in the world. According to a study published by the Centers for Disease Control and Prevention (CDC) in 2019, 1 in 31 hospital patients is estimated to have some kind of HAI. In addition, according to estimates by The European Centre for Disease Prevention and Control in 2019, ~4.1 million patients across Europe suffer due to HAIs every year. Furthermore, according to study published in the Journal of Antimicrobial Resistance & Infection Control in 2019, the incidence rate of HAIs in China was 3.62 per 1,000 patient days.

Out of this rate of incidence, respiratory tract infection accounted for 43.80% of infections while bloodstream and urinary tract infections accounted for 15.74% and 12.69% of infections, respectively. The hospital visits and patient pool is likely to increase in the coming years due to the mounting prevalence of chronic conditions and outbreaks of infectious diseases. HAIs also contribute to this increasing population of patients. For instance, the World Health Organization (WHO) estimates published in 2019, 421 million hospitalizations are conducted worldwide every year. Of these, 42.7 million patients suffer from adverse reactions or infections acquired at healthcare settings. Also, according to the same estimates, 50.0% of these adverse events are preventable in developed countries. Thus, such rising prevalence of HAIs is one of the prominent factors driving the demand for ATP swab tests.

The implementation of safety measures to prevent the spread of COVID-19 is driving the adoption of adenosine triphosphate (ATP) swabs. Moreover, the major shift in focus toward microbial safety amid the pandemic is offering lucrative opportunities for the growth of the market players.

Based on type, the adenosine triphosphate (ATP) swab test market is segmented into free ATP test and microbial ATP test. The free ATP test segment held a larger share of the market in 2019; however, the microbial ATP test segment is estimated to register a higher CAGR during the forecast period. The rising number focus on food safety and sterilization on microbial level is estimated to offer lucrative opportunity for the microbial ATP test segment growth.

The adenosine triphosphate (ATP) swab test market, by application, is segmented into pharmaceutical and biotechnology companies, food and beverage, hospitals and diagnostics laboratories, and academic and research institutions. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2019, and it is estimated to register the highest CAGR during the forecast period.

The World Health Organization (WHO), Food and Drug Administration (FDA), National Health Service (NHS), and Centers for Disease Control and Prevention (CDC) are among the major primary and secondary sources referred to while preparing this report.

Key Topics Covered:

1. Introduction

2. Adenosine Triphosphate (ATP) Swab Test Market- Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Global Adenosine Triphosphate (ATP) Swab Test Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific - PEST Analysis
4.2.4 Middle East & Africa- PEST Analysis
4.2.5 South & Central America - PEST Analysis
4.3 Expert Opinion

5. Adenosine Triphosphate (ATP) Swab Test Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Healthcare-Associated Infections (HAI)
5.1.2 Increasing Emphasis on Food Safety
5.2 Market Restraint
5.2.1 Limitations of ATP Swab Tests
5.3 Market Opportunity
5.3.1 Growing Spending on Patient Safety and Care
5.4 Future Trend
5.4.1 Development of Adenylate (A3) Concentration Based Modern Sterility Monitoring System
5.5 Impact Analysis

6. Adenosine Triphosphate (ATP) Swab Test Market - Global Analysis
6.1 Global Adenosine Triphosphate (ATP) Swab Test Market Revenue Forecast and Analysis
6.2 Global Adenosine Triphosphate (ATP) Swab Test Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players

7. Adenosine Triphosphate (ATP) Swab Test Market Analysis and Forecasts To 2027 -Type

8. Adenosine Triphosphate (ATP) Swab Test Market Analysis and Forecasts To 2027 - Application

9. Adenosine Triphosphate (ATP) Swab Test Analysis and Forecasts To 2027 - Geographical Analysis

10. Impact Of COVID-19 Pandemic on Global Adenosine Triphosphate (ATP) Swab Test Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
10.2 Europe: Impact Assessment Of COVID-19 Pandemic
10.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
10.5 South and Central America: Impact Assessment of COVID-19 Pandemic

11. Adenosine Triphosphate (ATP) Swab Test Market -Industry Landscape
11.1 Overview
11.2 Recent Growth Strategies in The Adenosine Triphosphate (ATP) Swab Test Market

12. Company Profiles
12.1 3M
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Hygiena, LLC
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Charm Sciences
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Kikkoman Biochemifa Co
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Neogen Corporation
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Ecolab
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Ruhof Healthcare Corporation
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 LuminUltra Technologies Ltd.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Promicol
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
12.11 PCE Instruments
12.11.1 Key Facts
12.11.2 Business Description
12.11.3 Products and Services
12.11.4 Financial Overview
12.11.5 SWOT Analysis
12.11.6 Key Developments
12.12 Promega Corporation
12.12.1 Key Facts
12.12.2 Business Description
12.12.3 Products and Services
12.12.4 Financial Overview
12.12.5 SWOT Analysis
12.12.6 Key Developments
12.13.1 Key Facts
12.13.2 Business Description
12.13.3 Products and Services
12.13.4 Financial Overview
12.13.5 SWOT Analysis
12.13.6 Key Developments

13. Appendix

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900